INTRODUCTION:
Malignant skin diseases are on the rise. A review of the scientific literature reveals only a few case reports documenting the development of malignant lesions triggered by tattoos. Given an estimated 10 % prevalence of tattooed individuals in Europe, an increase in tattoo-associated skin tumors is likely to occur in coming years.
MATERIAL AND METHODS:
All patient cases of post-tattoo skin malignancies -including squamous cell carcinoma (SCC), basal cell carcinoma, and malignant melanoma -were analysed (source: Pubmed / all publications up to March 2017). Parameters assessed included composition of tattoo ink, site of tattoo placement, personal or family history of skin cancer, type of skin cancer diagnosed, and time interval from tattooing to diagnosis.
RESULTS:
Pubmed search located 51 publications about tattoo associated skin cancer with a total of 63 cases in these reports. Furthermore, one new unpublished case report with SCC-formation after tattooing is presented -finally summing up to 64 cases. Usage of black and dark blue inks was associated with 58 % of all skin cancers after tattooing. Usage of red ink was associated with 34 % of all skin cancers after tattooing -including 60 % of all SCCs and 73 % of keratoacanthomas. Furthermore obvious differences in time interval between tattooing and first diagnosis of skin cancer were detected for each kind of skin cancer.
CONCLUSION:
Overall, there is a certain risk for skin malignancies due to tattooing, which cannot be neglected. Black, dark blue, and in particular red inks are associated with the occurrence of malignant skin lesions after tattooing. A more in-depth review of the link between tattoo ink and malignant transformation is strongly recommended by the authors.
ESTIMATION OF HEALTH CARE SYSTEM COSTS IN TREATING NON MELANOMA SKIN CANCER
Cozma Cristina-Nicoleta, Raducu Laura, Avino Adelaida, Sinescu Ruxandra Diana, Jecan Radu-Cristian, ROMANIA
INTRODUCTION:
Non melanoma skin cancer is the most common type of cancer, with an increased incidence over the past years. Presently, every year are diagnosed globally between 2 and 3 million of non melanoma skin cancers, 80% of these are usually basal cell carcinomas and 20% squamous cell carcinoma. Because of the increasing incidence, non melanoma skin cancer became a problem for health care services due to patient lower productivity and treatment costs.
Even though mortality is rare, within 1%, a lot of patients require extensive surgery, being exposed to additional anesthesia risks.
MATERIAL AND METHOD:
The present study is a retrospective study, realized over a 2 year period of time, including 150 patients treated in the Plastic Surgery Department of Emergency Clinical Hospital "Prof. Dr. Agrippa Ionescu". Descriptive data analysis was realized and the costs of each surgery were evaluated considering the necessity of general or local anesthesia, hospitalization days and additional imaging tests.
RESULTS:
Non melanoma skin cancers treated were basal cell carcinoma in 83,3% of cases and squamous cell carcinoma in 16,7 % of cases. Costs were higher in patients with bigger lesions, due to the necessity of general anesthesia required for extensive surgery and longer hospitalization days
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Abstracts EPSRC (p<0,05). The mean value of hospitalization days was 3.5, being correlated with the difficulty of surgical intervention (p=0,003). The average cost of a surgery with local anesthesia in a patient with no additional comorbidities is 200 euro in comparison with 650 euro for general anesthesia and additional comorbidities. Higher costs were also associated with rural provenience and squamous cell carcinoma due to the necessity of performing additional imaging tests, but were no correlated with older age.
CONCLUSIONS:
Considering the costs, non melanoma skin cancer became one of the main concerns for public health care system in developed countries. Romania doesn't have an evaluation of real costs for every patient and the importance of prevention or early detection.
People from rural areas have a lower medical education and consult their general practitioner in advanced cases, which leads to the necessity of extensive surgery and reconstruction with higher costs and consequences for their appearance and self-esteem.
GROWTH INHIBITION AFTER COMBINATION DRUG TREATMENT FOR 3D CO-CULTURE IN WILD TYPE AND V600E MUTANT BRAF MELANOMA TUMOUR CELLS

Alina Chelmus, Dragos Pieptu, Eric Tang, ROMANIA
INTRODUCTION: Melanoma has an aggressive phenotype with a high rate of morbidity and mortality. Tumour stromal environment heterogeneity and high drug resistance coupled with complex organ structure, makes the treatment for aggressive forms a medical challenge.
OBJECTIVE:
As part of an EU FP7 AIDPATH programme, we evaluated the phenotypic behaviour of wild type and V600E BRAF mutated melanoma tumour cells in 3D co-culture treated under different culture conditions.
MATERIALS AND METHODS:
Melanoma cell lines were transfected with Lentivirus-RFP and used to develop four different 3D co-culture models with normal human dermal fibroblasts (NHDF) and two primary stem cells (bone marrow or adipose derived stem cells). All cultures were treated with a BRAF and MEK inhibitors on day 3, in either monotherapy or drug combination. The morphological behaviour of these four culture models was studied when the microtissue was grown on a fibroblast feeding layer. Spheroid morphology and viability were evaluated using bright field and fluorescence imaging.
RESULTS:
The growth inhibition after drug treatment revealed statistically differential response between the wild type and BRAF mutant constructs, under different co-culture conditions. There was no differential in responses to drug treatment when different stem cells were used. In contrast, when the 3D microtissues were seeded onto the NHDF feeder layer, the melanoma monoculture expanded at a much higher rate than the co-culture in the first days of culture, although all four culture conditions result in similar morphology after day 10.
CONCLUSIONS:
This novel 3D constructs may offer an enhanced in vitro model for drug evaluation, with a better translation to clinical settings.
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LIFE-SAVING SURGICAL EXCISION OF GIANT MALIGNANT MELANOMA METASTASIS
Dumitrache S., Slavescu D., Capatina R., Gheorghe A.A., Iacob I., Giuglea C., ROMANIA INTRODUCTION: Surgical excision of malignant melanoma is critical for establishing the diagnosis but also for complete management. The prognosis for stage IV melanoma is poor, with only 10% to 15% of patients living past 5 years. Being the most deadly form of skin cancer, the malignant melanoma metastasis excision represents a palliative treatment.
MATERIAL AND METHODS:
After evaluating the general status and establishing the staging of malignant melanoma in a 66 year old man, we decided to excise a giant left laterocervical metastasis. After a thorough analysis of imaging investigations we performed a radical neck dissection
